Childhood ALL, Malaria, Vector Borne Diseases
Conditions
Keywords
malaria, cluster randomised trial, children, vector borne diseases, Nigeria, Internally Displaced People camps
Brief summary
The aim of this study is to determine the effectiveness of a new spatial repellent (called Mesh) at repelling multiple disease vectors and, reducing clinical malaria rates in temporary shelters and camp settings. The design of the study will be a two-armed cluster randomised trial. By conducting the research in challenging camp settings in the north of Nigeria, the MENTOR Initiative aims to determine whether Mesh can be effective in harsh camp conditions where communities are living in conflict area temporary shelters.
Interventions
COMBINATION_PRODUCTMesh - spatial repellent impregnated with transfluthrin (2500mg)
Mesh is one of the first spatial repellent tools to provide long-lasting protection to users, with predicted efficacy of 6-months. The active ingredient of Mesh is transfluthrin, a fast-acting volatile pyrethroid with low persistency, which can act either by killing or via sublethal toxicity that causes deviation (repellency) in host attraction, reducing host-contact and risk of infectious bites. The chemical passively releases into the air and interacts with vector odour receptors causing irritation. The design of Mesh is simple with a transfluthrin-infused sheet protected by plastic mesh and encased in a plastic frame. Mesh will be distributed to the intervention arm only.
BEHAVIORALInformation and Education Campaigns (IEC)
IEC campaigns will formally encourage breeding site management through; good practice household-level water storage (covering and cleaning of water storage containers) and waste management (removal of potential breeding sites in and around the home) using leaflets and word of mouth. IEC will be conducted in both arms.
DIAGNOSTIC_TESTtest and treat malaria cases
All children in the cohort (both arms) will be tested by rapid diagnostic testing (RDT) monthly. If any children test positive, they will be treated with a course of 3-day artemisinin combination therapy (ACT) according to standard protocol and local guidelines. All children in the cohort will receive ACT to provide clearance of any malaria parasites during the baseline of the study.
Sponsors
Liverpool School of Tropical Medicine
University of Maiduguri
US government
SCJohnson
The Mentor Initiative
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Masking description
Neither the deliverers of the intervention nor the outcome assessors are blinded to the group allocations.
Eligibility
Sex/Gender
ALL
Age
6 Years to 10 Years
Healthy volunteers
Yes
Inclusion criteria
* Shelters with 1 or more children from 6-10 years old * Shelters with an adult/head of the household
Exclusion criteria
* Shelters without children from 6-10 years old
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| entomological outcome: vector density | 7 months | the relative infestation rate of disease vectors (females of any of Anopheles malaria vectors, Aedes aegypti, or phlebotomine sand flies |
| epidemiological outcome: malaria incidence | 7 months | Malaria incidence will be estimated as the total number of malaria episodes per person over the course of the trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| feasibility, acceptance and uptake of Mesh | 7 months | To measure community and household acceptance and uptake of Mesh, a questionnaire will be conducted with the Mesh-receiving households. |
Countries
United Kingdom
Outcome results
None listed